DSIP (Delta Sleep-Inducing Peptide)
An investigational neuropeptide studied for sleep, stress regulation, and recovery; evidence is limited and mixed.
OVERVIEW
DSIP is a naturally occurring neuropeptide studied for possible effects on sleep quality, stress response, recovery, and nervous-system regulation. Findings are limited and mixed, and it is not an FDA-approved drug.
Proposed Mechanisms
The exact mechanism is not established. Research has explored neuroregulatory effects involving sleep, stress, endocrine signaling, and nervous-system balance.
Potential Applications
• Sleep-quality research • Stress-regulation research • Recovery research
Pharmacokinetics
The source draft cited a plasma half-life of approximately 7–15 minutes with potentially longer downstream signaling; robust human data are limited.
Dosing
No FDA-approved or evidence-based human therapeutic dose was supplied. Do not publish a protocol as established clinical guidance.
Monitoring
No standardized monitoring protocol; research oversight may assess sleep outcomes, daytime function, and adverse effects.
Side Effects
Reported as generally tolerated in limited sources, but long-term human safety is not established.
Contraindications
No FDA-approved labeling or established contraindication profile; clinician review is required.
FDA/Investigational Status
Not FDA-approved. FDA enforcement materials have identified marketed DSIP products as unapproved new drugs.
Disclaimer/Notes
Educational resource only. State clearly that evidence is preliminary and mixed.
Clinical Review Status
Clinical + legal review required before publishing